Baidu
map

Indian J Otolaryngol Head Neck Surg:补充维生素D对过敏性鼻炎的疗效

2021-06-27 AlexYang MedSci原创

过敏性鼻炎是最常见的慢性鼻炎类型,影响到10-20%的人口,而且有证据表明,这种疾病的发病率正在增加。严重的过敏性鼻炎影响生活质量、睡眠和工作表现。尽管最近有流行病学证据表明,过敏性鼻炎的发病率在全球

过敏性鼻炎是最常见的慢性鼻炎类型,影响到10-20%的人口,而且有证据表明,这种疾病的发病率正在增加。严重的过敏性鼻炎影响生活质量、睡眠和工作表现。尽管最近有流行病学证据表明,过敏性鼻炎的发病率在全球范围内不断上升,但只有不到12%的过敏患者向医生寻求医疗建议,导致对过敏性鼻炎认识不足、误诊和无效治疗。

过敏性鼻炎是全球公认的最常见的鼻炎之一。虽然它不是一个威胁生命的实体,但与生活质量的严重损害有关,并给患者带来巨大的经济负担。多年来,过敏性鼻炎患者的数量大幅增加,世界各地的研究人员发现过敏性鼻炎患者的维生素D水平较低

近期,有研究人员进行了一项随机对照试验,87名受试者分为2组。在治疗前对这些病人进行鼻腔症状总分(TNSS)记录。研究人员对A组给予鼻内类固醇喷雾,而B组在鼻内类固醇喷雾的同时补充维生素D,并对治疗后的TNSS分数和鼻炎控制评估测试分数进行了计算和分析。

结果发现,38名患者有严重的维生素D缺乏症,平均TNSS评分为11.3,而49名患者的维生素D水平不足,平均TNSS为8.6。A组治疗前的TNSS评分为12.5±2.68,而治疗后的评分为8.98±1.009,A组的两项评分差异为3.52。B组(氟替卡松和维生素D)的治疗前TNSS评分为11.64±3.09,而治疗后评分为6.3±1.45,A组的两项评分相差5.34。A组和B组的治疗后RCAT分别为19.72±2.84和28.2±1.53,两组之间的差异为8.48。

两组TNSS评分均差的统计学分析

综上所述,虽然鼻内类固醇喷雾剂是治疗过敏性鼻炎的一线药物,但如果同时使用维生素D补充剂,可以起到更好地缓解症状的作用。研究人员鼓励进行更多的多机构研究,以确认结果的有效性,然后再将其纳入标准治疗指南。

原始出处:

Bhanu Bhardwaj , Jaskaran Singh. Efficacy of Vitamin D Supplementation in Allergic Rhinitis. Indian J Otolaryngol Head Neck Surg. Jun 2021

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639797, encodeId=4a231639e9711, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 28 10:01:57 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047424, encodeId=fa9d204e424d1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 27 01:01:57 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044192, encodeId=584b204419274, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 07 13:01:57 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469183, encodeId=95c614691838a, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Jun 29 12:01:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032992, encodeId=31611032992bc, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Jun 28 00:01:57 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639797, encodeId=4a231639e9711, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 28 10:01:57 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047424, encodeId=fa9d204e424d1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 27 01:01:57 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044192, encodeId=584b204419274, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 07 13:01:57 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469183, encodeId=95c614691838a, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Jun 29 12:01:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032992, encodeId=31611032992bc, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Jun 28 00:01:57 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639797, encodeId=4a231639e9711, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 28 10:01:57 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047424, encodeId=fa9d204e424d1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 27 01:01:57 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044192, encodeId=584b204419274, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 07 13:01:57 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469183, encodeId=95c614691838a, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Jun 29 12:01:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032992, encodeId=31611032992bc, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Jun 28 00:01:57 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639797, encodeId=4a231639e9711, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 28 10:01:57 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047424, encodeId=fa9d204e424d1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 27 01:01:57 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044192, encodeId=584b204419274, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 07 13:01:57 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469183, encodeId=95c614691838a, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Jun 29 12:01:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032992, encodeId=31611032992bc, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Jun 28 00:01:57 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-29 xiaogang319
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639797, encodeId=4a231639e9711, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 28 10:01:57 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047424, encodeId=fa9d204e424d1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 27 01:01:57 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044192, encodeId=584b204419274, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Jul 07 13:01:57 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469183, encodeId=95c614691838a, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Jun 29 12:01:57 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032992, encodeId=31611032992bc, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Jun 28 00:01:57 CST 2021, time=2021-06-28, status=1, ipAttribution=)]
    2021-06-28 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

J Cardiovasc Pharmacol Ther:补充维生素D可减少冠状动脉搭桥术患者的炎症水平

维生素D在免疫系统和炎症细胞因子的调节中起着重要作用。冠状动脉搭桥术(CABG)和心肺分流术(CPB)与炎症反应有关。近日,一项新的研究探讨了维生素D治疗对CABG后形成的细胞凋亡和炎症变化的影响,研

JCC: 肠上皮中维生素D受体的过表达可通过上调紧密连接蛋白Claudin-15来预防结肠炎的发生

维生素D受体(VDR)的功能障碍通过调节自噬,免疫反应和粘膜通透性而参与了IBD的发病。有研究证实,VDR直接控制细胞旁紧密连接蛋白Claudin-2。

Nat Commun:母体孕前维生素D状况影响后代性别比例

最近的一项研究结果显示,在1228名试图怀孕的妇女中,孕前25-羟维生素D的浓度与活产男婴呈正相关,在高敏C反应蛋白(一种系统性低度炎症的标志物)升高的妇女中,该相关性明显增强。

JAHA:补充维生素D对心血管和血糖生物标志物的影响

大剂量维生素D补充不能改善血糖、炎症、神经激素激活或脂质的生物标志物。

Front Immunol:维生素D研究揭示了对免疫系统的影响

维生素D是身体对阳光的反应而产生的,并且经常因其对健康的好处而受到称赞。研究人员发现,它也会影响免疫系统的关键细胞-树突状细胞(DC),它是一种特殊的哨兵细胞,连接天然免疫和适应性免疫反应。

Nutrients:维生素D是否可用于治疗COVID-19 ?

COVID-19 世界大流行已成为数代人以来最大和最严重的公共卫生问题,但是还未有最佳的治疗方案。有研究提出使用维生素D来治疗COVID-19,本研究中,研究人员探究了COVID-19的死亡率是否受血

Baidu
map
Baidu
map
Baidu
map